GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: EZM-0414
Compound class:
Synthetic organic
Comment: EZM0414 is a first-in-class, oral SETD2 histone methyl transferase inhibitor that was developed by Epizyme for anti-cancer potential. Its chemical structure was disclosed at the AACR spring meeting in 2022 (link to download poster pdf here).
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| EZM0414 has progressed to early stage clinical evaluation in patients with relapsed/refractory haematologic malignancies. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05121103 | A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 Interventional | Epizyme, Inc. | ||